Net sales increased 19% to $82.3 million versus $69.2 million last year; ahead of previous guidance range of $71 million to $74 million.

Teva net sales for the third quarter increased to $10 million compared with $9.7 million for the same period last year. Teva’s performance was driven by a positive reaction to a limited introduction of closed toe footwear combined with solid sales of the traditional sandal offering.

Share this story: